- Home
- XCBE vs TARA Comparison
XCBE vs TARA Comparison
Compare XCBE & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$5.44
Company Overview
Basic Information| Metric | XCBE | TARA |
|---|---|---|
| Founded | 2025 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.5M | 292.9M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | XCBE | TARA |
|---|---|---|
| Price | $9.91 | $5.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.40 |
| AVG Volume (30 Days) | 73.3K | ★ 537.8K |
| Earning Date | N/A | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.75 | $2.77 |
| 52 Week High | $9.91 | $7.82 |
Technical Indicators
Market Signals| Indicator | XCBE | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 66.76 | 55.89 |
| Support Level | $9.83 | $4.92 |
| Resistance Level | N/A | $5.96 |
| Average True Range (ATR) | 0.01 | 0.25 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 100.00 | 78.96 |
Price Performance
Historical Comparison XCBE
TARA
About XCBE X3 Acquisition Corp. Ltd. Class A Ordinary Shares
X3 Acquisition Corp Ltd is a blank check company.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.